Rosuvastatin reduced major cardiovascular events in patients at intermediate cardiovascular risk

被引：0
|
作者：
Eaton, Charles B. [1 ]
机构：
[1] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2016年 / 165卷 / 02期
关键词：
RANDOMIZED CONTROLLED-TRIAL; PRIMARY PREVENTION; CHOLESTEROL; CORONARY; AVERAGE; DISEASE; WOMEN; MEN;
D O I：
10.7326/ACPJC-2016-165-2-006
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：JC6 / +
页数：3
相关论文
共 50 条
  • [31] Reduced cardiovascular risk factors and cardiovascular events in idiopathic Parkinson's disease (IPD) patients compared with controls
    Rabey, J. M.
    Abruzzese, G.
    Prokhorov, T.
    Bonuccelli, U.
    [J]. MOVEMENT DISORDERS, 2012, 27 : S444 - S445
  • [32] MAJOR ADVERSE CARDIOVASCULAR EVENTS: RISK FACTORS IN PATIENTS WITH RA TREATED WITH TOFACITINIB
    Charles-Schoeman, C.
    Valdez, H.
    Soma, K.
    Hwang, L.
    DeMasi, R.
    Boy, M.
    McInnes, I. B.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1034 - 1035
  • [33] Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis
    Bissonnette, Robert
    Kerdel, Francisco
    Naldi, Luigi
    Papp, Kim
    Galindo, Claudia
    Langholff, Wayne
    Tang, K. L.
    Szapary, Philippe
    Fakharzadeh, Steven
    Srivastava, Bhaskar
    Goyal, Kavitha
    Gottlieb, Alice B.
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2017, 16 (10) : 1002 - 1013
  • [34] Effects of Aclidinium Bromide on Major Adverse Cardiovascular Events and COPD Exacerbations in Patients with COPD and Cardiovascular Risk Factors
    Wise, R. A.
    Scirica, B. M.
    Schoenfeld, D. A.
    Daoud, S. Z.
    Roman, J.
    Reisner, C.
    Gil, E. Garcia
    Chapman, K. R.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [35] The risk of major adverse cardiovascular events associated with the use of hypnotics in patients with insomnia
    El-Solh, Ali A.
    Lawson, Yolanda
    Wilding, Gregory E.
    [J]. SLEEP HEALTH, 2023, 9 (05) : 717 - 725
  • [36] Major Adverse Cardiovascular Events: Risk Factors in Patients with RA Treated with Tofacitinib
    Charles-Schoeman, Christina
    Valdez, Hernan
    Soma, Koshika
    Hwang, Lie-Ju
    DeMasi, Ryan
    Boy, Mary
    McInnes, Iain B.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [37] Combination Therapy of Rosuvastatin and Ezetimibe in Patients with High Cardiovascular Risk
    Yang, Young-June
    Lee, Sang-Hak
    Kim, Byung Soo
    Cho, Yun-Kyeong
    Cho, Hyun-Jai
    Cho, Kyoung Im
    Kim, Seok-Yeon
    Ryu, Jae Kean
    Cho, Jin-Man
    Park, Joong-Ii
    Park, Jong-Seon
    Park, Chang Gyu
    Chun, Woo Jung
    Kim, Myung-A
    Jin, Dong-Kyu
    Lee, Namho
    Kim, Byung Jin
    Koh, Kwang Kon
    Suh, Jon
    Lee, Seung-Hwan
    Lee, Byoung-Kwon
    Oh, Seung-Jin
    Jin, Han-Young
    Ahn, Youngkeun
    Lees, Sang-Gon
    Bae, Jang-Ho
    Park, Woo Jung
    Lee, Sang-Chol
    Lee, Han Cheol
    Lee, Jaewon
    Park, Cheolwon
    Lee, Backhwan
    Jang, Yangsoo
    [J]. CLINICAL THERAPEUTICS, 2017, 39 (01) : 107 - 117
  • [38] Omega-3 Fatty Acids Effect on Major Cardiovascular Events in Patients at High Cardiovascular Risk Reply
    Nissen, Steven E.
    Lincoff, A. Michael
    Nicholls, Stephen J.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (13): : 1334 - 1335
  • [39] Rosuvastatin versus atorvastatin for secondary prevention in cardiovascular risk patients
    Schanz, Moritz
    Latus, Joerg
    [J]. NEPHROLOGIE, 2024,
  • [40] Household Air Pollution, Intermediate Outcomes, and Major Adverse Cardiovascular Events
    Essouma, Mickael
    Bigna, Jean Joel R.
    Noubiap, Jean Jacques N.
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2016, 18 (05): : 479 - 480
12345